GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Total Inventories

Viela Bio (Viela Bio) Total Inventories : $0.00 Mil (As of Dec. 2020)


View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Total Inventories?

Viela Bio's total inventories for the quarter that ended in Dec. 2020 was $0.00 Mil. Viela Bio's average total inventories from the quarter that ended in Sep. 2020 to the quarter that ended in Dec. 2020 was $0.22 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Viela Bio's Net-Net Working Capital per share for the quarter that ended in Dec. 2020 was $5.91.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Viela Bio's Days Inventory for the three months ended in Dec. 2020 was 14.38.

Inventory Turnover measures how fast the company turns over its inventory within a year. Viela Bio's Inventory Turnover for the quarter that ended in Dec. 2020 was 6.35.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Viela Bio's Inventory-to-Revenue for the quarter that ended in Dec. 2020 was 0.02.


Viela Bio Total Inventories Historical Data

The historical data trend for Viela Bio's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Total Inventories Chart

Viela Bio Annual Data
Trend Dec18 Dec19 Dec20
Total Inventories
- - -

Viela Bio Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.44 -

Viela Bio Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Viela Bio  (NAS:VIE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Viela Bio's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2020 is

Net-Net Working Capital Per Share (Q: Dec. 2020 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(367.687+0.75 * 5.385+0.5 * 0-47.429
-0-0)/54.8915
=5.91

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Viela Bio's Days Inventory for the three months ended in Dec. 2020 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2020 )/Cost of Goods Sold (Q: Dec. 2020 )*Days in Period
=0.219/1.39*365 / 4
=14.38

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Viela Bio's Inventory Turnover for the quarter that ended in Dec. 2020 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2020 ) / Average Total Inventories (Q: Dec. 2020 )
=1.39 / 0.219
=6.35

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Viela Bio's Inventory to Revenue for the quarter that ended in Dec. 2020 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=0.219 / 9.336
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Viela Bio Total Inventories Related Terms

Thank you for viewing the detailed overview of Viela Bio's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Viela Bio (Viela Bio) Business Description

Traded in Other Exchanges
N/A
Address
One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Executives
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu director 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd 10 percent owner SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund 10 percent owner CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao director, officer: Chief Executive Officer 10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz officer: VP, Head of Commercial C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878

Viela Bio (Viela Bio) Headlines

From GuruFocus